Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3491-3497

  Flattery, Amy M ^a   Hickey, Emily ^a   Gill, Charles J ^a   Powles, Mary Ann ^a   Misura, Andrew S ^a   Galgoci, Andrew M ^a   Ellis, Joan D ^a   Zhang, Rena ^a   Sandhu, Punam ^a   Ronan, John ^a   Abruzzo, George K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DISEASE; CANDIDA ALBICANS; CENTRAL NERVOUS SYSTEM CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; ENCEPHALITIS; FUNGUS CULTURE; INOCULATION; INVASIVE CANDIDIASIS; KIDNEY DISEASE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTIFUNGAL AGENTS; BRAIN; CANDIDIASIS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; ECHINOCANDINS; KIDNEY; MICE;

EID: 79959212504     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01328-10     Document Type: Article

References (16)

1. Benjamin, D. K. J., et al. 2006. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopment outcomes at 18 to 22 months. Pediatrics 117:84.
2. Fernandez, M., E. H. Moylett, D. E. Noyola, and C. J. Baker. 2000. Candidal meningitis in neonates: a 10-year review. Clin. Infect. Dis. 31:458-463.
3. Friedman, S., S. E. Richardson, S. E. Jacobs, and K. O'Brien. 2000. Systemic Candida infection in extremely low birth weight infants; short term morbidity and long term neurodevelopmental outcome. Pediatr. Infect. Dis. J. 19:499-504.
4. Groll, A. H., et al. 2000. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182:274-282.
5. Groll, A. H., E. Roilides, and T. J. Walsh. 2009. Fungal infections in pediatric patients, p. 481-499. In E. J. Anaissie, M. R. McGinnis, and M. A. Pfaller (ed.), Clinical mycology, 2nd ed. Elsevier, Philadelphia, PA.
6. Holm, S. 1979. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6:65-70.
7. Hope, W., et al. 2008. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J. Infect. Dis. 197:163-171.
8. Hope, W., S. Shoham, and T. Walsh. 2007. The pharmacology and clinical use of caspofungin. Expert Opin. Drug Metab. Toxicol 3:263-274.
9. Kang, C., M. Rouse, J. Mandrekar, J. Steckelberg, and R. Patel. 2009. Anidulafungin treatment of candidal central nervous system infection in a murine model. Antimicrob. Agents Chemother. 53:3576-3578.
10. Kim, R., D. Khachikian, and A. Reboli. 2007. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin. Pharmacother. 8:1479-1492.
11. Merck & Co., Inc. 2009. Cancidas (caspofungin acetate) prescribing information. Merck & Co., Inc., Rahway, NJ.
12. Natarajan, G., M. Lulic-Botica, C. Rongkavilit, A. Pappas, and M. Bedard. 2005. Experience with caspofungin in the treatment of persistent fungemia in neonates. J. Perinatol. 25:770-777. (Pubitemid 43019041)
13. Odio, D., et al. 2004. Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. 23:1093-1097.
14. Pappas, P., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
15. Sáez-Llorenz, X., et al. 2009. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob. Agents Chemother. 53:869-875.
16. Walsh, T., et al. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49:4536-4545.